Smartening Africa’s Drug Supply Chain with IBM AI

By Crystal Lubbe

November 27, 2024

The article from Bizcommunity titled “African Drug Supply Chain Gets Smarter with IBM-Powered AI Platform” highlights a major initiative aimed at enhancing the pharmaceutical supply chain in Africa through the use of advanced technologies, focusing on AI and digital solutions. This initiative revolves around the establishment of the Pulse platform by NABP, designed to improve efficiency and transparency within the African drug supply chain.

Collaboration and Partnerships

This initiative involves a collaboration between Prosper Africa, USAID’s e-Trade Alliance, IBM Consulting, and the National Association of Boards of Pharmacy (NABP) to launch a platform called Pulse by NABP in South Africa. This partnership aims to connect US and global pharmaceutical companies like Pfizer and Roche with African distributors and pharmacies, proving critical in strengthening the African drug supply chain.

Use of AI and Digital Solutions

The Pulse platform leverages IBM’s Watson AI capabilities to enhance the traceability of drugs exported to Africa. This initiative not only improves supply chain visibility but also reduces spoilage, ensuring consistent stock levels. Furthermore, it fosters profitable partnerships with international suppliers. IBM Consulting will utilize its AI-powered delivery platform, IBM Consulting Advantage, to collect and analyse product scan data, enabling pharmacies and retailers to make more informed, data-driven decisions. Ultimately, this enhances the African drug supply chain.

Market Opportunities and Challenges

The African pharmaceutical market, valued at $26.85 billion in 2023, is projected to grow 3.4% annually from 2024 to 2030. However, fragmented supply chains, poor infrastructure, and diverse regulations hinder efficient pharmaceutical distribution across African countries. These challenges result in supply inefficiencies, limited product availability, and higher patient costs, complicating efforts to improve the drug supply chain.

Benefits of the Platform

– Enhanced Traceability: The platform improves the ability to identify and trace medications, ensuring greater security in the drug supply chain.
– Inventory Optimization: AI tools help minimise stockouts and overstock situations by optimising inventory levels.
– Improved Operations: The platform enhances operations for African distributors and pharmacies, leading to more efficient and profitable supply chains.
– Economic and Social Impact: This initiative enhances economic growth and health by improving supply chain visibility and creating a transparent, accessible medication market.

Training and Capacity Building

IBM will offer training on AI tools like Watsonx.ai to help African pharmacies and retailers utilise data-driven decision-making effectively. This training is part of a broader strategy to build resilient ecosystems that drive economic growth and societal impact.

Public-Private Collaboration

Altogether, collaboration between public and private entities undoubtedly reflects the potential to drive both economic growth and health improvements. Furthermore, emphasises the use of technology and expertise to enhance transparency and foster trust in vital industries like healthcare.

The Pulse by NABP, powered by IBM AI, addresses Africa’s pharmaceutical supply chain challenges through traceability and operational efficiency.
This initiative benefits US companies and African consumers by improving medication access and strengthening the African drug supply chain.

Reference url

Recent Posts

Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications

By João L. Carapinha

April 24, 2026

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies

By João L. Carapinha

April 23, 2026

Europe Pharmaceutical Access is at a “very critical point,” according to Emer Cooke, Executive Director of the European Medicines Agency (EMA). The number of new drug launches in Europe has fallen by more than a third since U.S. President Donald Trump’s “most-favored-nation” (MFN) drug pricing po...
Zanidatamab Biliary Cancer Therapy: Advancing Targeted Treatment for HER2-Positive Patients

By HEOR Staff Writer

Zanidatamab biliary cancer therapy has been recommended by NICE for routine use in the NHS to treat adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer who have received at least one prior line of systemic therapy. Targeted Option for Rare Aggre...